Overview
Researchers want to learn if MK-1084 given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation.
The goals of this study are to learn:
- How many people have the cancer respond (get smaller or go away) to MK-1084 alone or with cetuximab and how these responses compare
- About the safety of MK-1084 alone or with cetuximab and if people tolerate the treatments.
Eligibility
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has locally advanced unresectable or metastatic solid tumor malignancy other than colorectal cancer and has progressed on, or following, standard of care systemic treatment
- Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system metastases and/or carcinomatous meningitis and/or primary brain tumors
- Has active infection, other than those permitted per protocol, requiring systemic therapy
- Has not adequately recovered from major surgery or has ongoing surgical complications